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Edited by Varda RotterAbstract The tumor suppressor p53 regulates the expression of
various genes that promote apoptosis. PIG11 (P53-induced gene
11), also referred to as TP53I11 (tumor protein p53 inducible
protein 11), is a direct p53 target gene. Recent data demon-
strated that PIG11 was up-regulated markedly in arsenic
trioxide induced apoptosis by DDRT-PCR, suggesting a new
class of p53 target genes that sensitize cells to the eﬀects of
chemotherapeutic agents. In this study, through the construction
of a recombinant GFP-PIG11 expression vector and transfection
of HEK293 cells with GFP or GFP-PIG11, the role of PIG11 in
apoptosis was analyzed. Results demonstrated that the percent-
age (11.38%) of apoptotic cells with GFP-PIG11 transfection
was higher than that (7.28%) of with only GFP transfection
(P<0:05). At 24 h after 1 lM of arsenic trioxide treatment,
apoptotic cells exhibited a signiﬁcant increase in the expression
of GFP-PIG11 (36.67%% 2.78), in contrast, 10.50%% 2.03
only GFP and 5.25%% 0.96 vehicle control (P< 0:01). In
addition, we showed that intracellular content of reactive oxygen
species (ROS) was 9.66% 0.52 in GFP-PIG11 transfection,
higher than 5.21% 0.08 in GFP only and 5.99% 0.45 in vehicle
control (P< 0:01). The above results suggest that overexpression
of PIG11 could induce cell apoptosis in the low levels and
enhanced the apoptotic eﬀects of arsenic trioxide. The process
could be involved in intracellular generation of ROS.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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PIG11 (P53-induced protein 11), also referred to as TP53I11
(tumor protein p53 inducible protein 11), is a p53 target gene
[1]. Mutations that inactivate the p53 tumor suppressor pro-
tein are the most common genetic aberrations known to occur
in human cancers. The best-described biological functions of
p53 are the induction of cell cycle arrest and apoptosis in re-
sponse to cellular stresses [2–4]. It is known that p53 is a
transcription factor that binds to speciﬁc sequences in DNA
and activates the transcription of target gene [5]. In recent
years, a number of p53 target genes have been identiﬁed that
mediate apoptosis including Fas, DR5/Killer, PERP, Bax,* Corresponding author. Fax: +86-10-64871293.
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doi:10.1016/j.febslet.2004.05.057Noxa, PUMA, Bid, P53AIPI, Pidd, Apaf-1, PEG3/Pw1, IGF-
BP3, PIGs, Scotin, AIF, p53RDL1,PAC1, and Siah-1b [6–10].
Polyak et al. [1] initially reported the p53-induced genes (PIGs)
using the SAGE technique following p53 overexpression.
These PIGs were given numbers 1–13. In general, the set of
PIGs encode proteins that generate or respond to oxidative
stress. Such as PIG1 (galectin-7) which belongs to the galectin
family, members of which can stimulate superoxide produc-
tion. Expression of PIG1 results in enhanced cytochrome c
release during apoptosis [11]. PIG6 is a homologue of proline
oxidoreductase [12]. PIG8 may be the tumor suppressor genes
as suggested by its involvement in p53-induced apoptosis [13].
PIG12 is a novel member of the microsomal glutathine-S-
transferase family of gene [1]. The PIGs are direct downstream
targets that can be activated by p53 and trigger the apoptosis
in p53-dependent apoptosis pathway. Recently, some investi-
gators demonstrated that PIG11 were signiﬁcantly induced by
wild-type p53 in H1299 cells [14] and in ECV-304 cell [15]. But
the function and structure of PIG11 remain to be determined.
Our previous studies demonstrated that PIG11 was upregu-
lated markedly in As2O3 induced- apoptosis of MGC-803 cells
using diﬀerential display reverse transcription PCR (DDRT-
PCR) and the apoptosis can partially be inhibited by means of
anti-PIG11 oligonucleotide treatment [16]. Thus, it is of in-
terest for us to further study about PIG11.
In this study, a recombinant GFP-PIG11 expression vector
was constructed and transiently transfected into HEK293 cells.
It further demonstrated that there is a p53 consensus binding
site in the promoter of the PIG11 gene. PIG11 protein is a
cytoplasmic protein. The overexpression of PIG11 could in-
duce cell apoptosis in the low levels and enhanced the apop-
totic eﬀects of arsenic trioxide in HEK293 cells. The process
was involved in intracellular generation of ROS.2. Materials and methods
2.1. Construction of a recombinant GFP-PIG11 expressing vectors
PIG11 cDNA encoding amino acids were obtained by reverse tran-
scription-PCR (RT-PCR) of total RNA from MGC-803 cells with
As2O3 1 lM treatment for 24 h. The PCR product was puriﬁed and
subcloned into pcDNA3.1/NT-GFP mammalian expression vector us-
ing GFP Fusion TOPO TAExpressionKits (Invitrogen), according to
the manufacturer’s instruction. Subcloned PCR fragments were con-
ﬁrmed by sequencing with ABI 377 automated ﬂuorescence-based se-
quencer (Shanghai Gene Core Biotechnologies Co., Ltd., China). A
corrected nucleotide sequence for PIG11 is available from GeneBank/
EMBL/DDBJ, Accession No. BC003010.1.ation of European Biochemical Societies.
Fig. 1. A potential p53-binding site was identiﬁed in the promoter of
the PIG11 gene. The sequence that is underlined indicates the pair of
decamers with a minimal space between both decamers and containing
the smallest number of disparities with the consensus sequence (50-
PuPuPuC(A/T)(A/T)GPyPyPy-30, Pu¼G or A, Py¼C or T).
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protein
HEK293 cells (Human transformed primary embryonic kidney cells,
ATCCNo. CRL-1573) were grown at 37 Cwith 5%CO2 in PRMI 1640
culture medium with 10% FCS, 100 lg/ml streptomycin and 100 U/ml
penicillin. Cells were seeded onto grass coverslips placed in 6-well plates.
The cells were cultured in fresh medium for 24 h and were then tran-
siently transfected with expression vector encodingGFP-PIG11 orGFP
only using LipofectamineTM 2000 (Invitrogen) following the manufac-
turer’s recommendation. At 24 h after transiently transfection, the cells
were observed by ﬂuorescence microscope (Olympus, IX-71. AQUA-
COSMOS 2.0, Analysis software). GFP was excited at 488 nm and
ﬂuorescence emission was detected through a 505 nm long pass ﬁlter.
Average transfected eﬃciency was analyzed through ﬂow cytometry
(FACS).
2.3. Apoptosis assays
HEK293 cells were transiently transfected with GFP or GFP-PIG11
24 h later, and 1 lM of arsenic trioxide (As2O3, Sigma Chemical St.
Louis, MO, USA) for 24 h or untreatment. The cells were harvested by
trypsinization, washed in PBS, and then ﬁxed in 70% ethanol. After
washing cells twice with PBS, DNA was stained with propidium iodide
(50 lg/ml) containing 250 lg/ml ribonuclease A, followed by ﬂow
cytometry analysis (Coulter EPICS XL ﬂow cytometry). Percentage of
cells in sub-G1 phase was regarded as the percentage of apoptotic cells.
Morphologic charge of apoptotic cells was visualized and photo-
graphed under ﬂuorescence microscope after cells were stained with
Hoechst 33342.
2.4. Measurement of ROS
Superoxide production was determined by measuring the conversion
of dihydroethidium (DHE) to ethidium [17]. Brieﬂy, cells were tran-
siently transfected with GFP or GFP-PIG11 for 24 h. Cells were
washed in PBS, resuspended in 1 ml PBS, and DHE was added to each
sample (ﬁnal concentration 2 lM). Samples were immediately vortexed
and incubated at 37 C in the dark for 30 min. After incubation, cells
were washed with PBS, protected from light, and analyzed by FACS
within 10 min. Excitation peak of ethidium is at 518 nm, ﬂuorescence
emission peak is at 605 nm.
2.5. Sequence analysis
The genomic sequence of PIG11 in human chromosome 11 (GI:
22038623) was analyzed for the p53 responsive element using the
PATCH software (www.gene-regulation.com_cgibin_pub_programs_
patch_bin_patch.cgi). The characteristic was predicted through the
SMART, SOSUI, PSORT and Predotar prediction program.
2.6. Statistics
All data are expressed as meansS.D. (standard deviation), statis-
tical signiﬁcance was assessed by the Student’s t-test.3. Results
3.1. Identiﬁcation of a putative p53 consensus site in the PIG11
gene and characteristic prediction of PIG11 protein
P53 is a transcription factor that binds to DNA in a se-
quence-speciﬁc manner to activate transcription of target
genes. The consensus DNA-binding sequence for p53 consists
of two repeats of the 10 bp motif 50-PuPuPuC(A/T)(A/
T)GPyPyPy-30 separated by o-10 bp [18]. To determine whe-
ther the PIG11 gene is a direct transcriptional target of p53
[1,19], 20 kb of the region of human chromosome 11 con-
taining the PIG11 locus was analyzed by using the PATCH
software. A putative p53 consensus binding site was identiﬁed
in the promoter region comprising nucleotides -1085/-1063, 50-
AcACAAGaCTatAAACAAGCCC-30. This DNA element
consists of the two decamers with 2 bp apart (see Fig. 1).
PIG11 protein is consisted of 121 amino acids. Molecular
weight 12.904 kDa and PI 8.24. Analysis for sequences ho-
mology by BLAST demonstrated that similar sequences hadnot been found, and no domain, repeats, motifs or features
could be predicted with conﬁdence using SMART Analysis.
SOSUI Analysis indicated that these amino acid sequences are
of a soluble protein. Possibility of located nucleon is 43.5%,
cytoplasma 34.8%, mitochondrion 13.0%, cytoskeleton 8.7%
through PSORT II prediction. We constructed a GFP–PIG11
fusion protein in this study, the results showed that the ma-
jority of GFP–PIG11 fusion protein was present in the cyto-
plasm, as control, GFP alone was evenly distributed in the
GFP–PIG11 fusion protein and the nucleus (Fig. 2). It sug-
gests that PIG11 could be a soluble cytoplasm protein.
3.2. Transfection and detection of GFP-PIG11 fusion protein in
HEK293 cells
In order to look for a biological role of PIG11, a fusion gene
was constructed consisting of GFP linked to the N-terminal of
PIG11 gene coding sequence, and HEK293 cells were trans-
fected with a control GFP vector or a GFP-PIG11 vector. We
have tested the MGC-803 cells used in the previous study [16],
but the transfection eﬃciency was very low. Hence, we used
HEK293 cells because it can be eﬃciently transfected with
expression vector. Average transfected eﬃciency at 24 h after
transient transfection was analyzed through FACS. The per-
centages of positive cells were 65.1–71.8% and 60.2–67.8% in
GFP only and GFP-PIG11, respectively.
3.3. Overexpression of PIG11 gene enhanced As2O3
induced-apoptosis in HEK293 cells
The transfected HEK293 cells with GFP or GFP-PIG11
were stained with Hoechst 33342. The observation of ﬂuores-
cence microscope showed that HEK293 cells with overex-
pression of PIG11 exhibited a signiﬁcant increase in apoptotic
cells (Fig. 3A, 1–3). Apoptotic cells were quantiﬁed by FACS
as the proportion of cells that had a DNA content of less than
2N (sub-G1DNA content) (Fig. 3B). The ﬂow cytometry scans
analysis indicated that 11.38% of the HEK293 cells population
was undergoing apoptosis after transfection with the GFP-
PIG11 vector. In contrast, 7.28% and 3.21% of the HEK293
cells were undergoing apoptosis with only GFP vector and
vehicle control, respectively (P < 0:05) (Fig. 3B and C). The
above results indicate that PIG11 fusion protein inﬂuenced cell
apoptosis in HEK293 cells.
HEK293 cells were transiently transfected with GFP or
GFP-PIG11 24 h later 1 lM of As2O3 was added to the above
Fig. 3. Overexpression of PIG11 gene involved apoptosis in the transfected HEK293 cells and enhanced As2O3 induced-apoptosis. The transfected
HEK293 cells with GFP or GFP-PIG11 were treated with 1 lM. of As2O3: Apoptotic cells were evaluated by FACS at 24 h after As2O3treatment.
(A) Apoptotic cells were determined by Hoechst 33342 staining (1: GFP-/As2O3-; 2: GFP+/As2O3-; 3: GFP-PIG11+/As2O3-; 4: GFP-/As2O3+; 5:
GFP +/As2O3+; 6: GFP-PIG11+/As2O3+). The typical apoptotic cells (see arrow in ﬁgure) showed nuclear condensation and fragment. (B) The sub-
G1 DNA content in GFP-positive cells represents apoptotic cells. (1: GFP-/As2O3- ; 2: GFP+/As2O3-; 3: GFP-PIG11+/As2O3-; 4: GFP-/As2O3+ ; 5:
GFP +/As2O3+; 6: GFP-PIG11+/As2O3+). (C) Data are presented as the meansS.D. of the percentage of apoptotic cells in three independent
experiments. P < 0:01 vs. other groups. P < 0:05 vs. GFP or control.
Fig. 2. Distribution of GFP-PIG11. Cells were photographed under a ﬂuorescence microscope at 24 h after GFP or GFP-PIG11 transient trans-
fection. GFP-PIG11 was distributed in the cytoplasma (right panel, arrow), while GFP was the homogenous distribution in cytoplasma and nucleus
(left panel, arrow). Magniﬁcations 400.
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Fig. 4. GFP-PIG11 fusion protein stimulated ROS production in
HEK293 cells. HEK293 cells were transiently transfected with GFP or
GFP-PIG11 for 24 h, and then were stained with DHE and analyzed
by FACS in total GFP-positive cells. The data were presented as the
meansS.D. of DHE ﬂuorescence from three experiments. P < 0:01
vs. GFP or control. (A) Fluorescence intensity for DHE in HEK293
cells without and with GFP or GFP-PIG11. (B) Single parameter in
HEK293 cells without and with GFP or GFP-PIG11.
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pression of PIG11 exhibited a signiﬁcant increase than the
samples without As2O3 treatment in apoptotic cells (Fig. 3A,
4–6). Apoptotic cells were quantiﬁed by FACS: 36.67% 2.78
GFP-PIG11 vs. 10.50% 2.03 only GFP and vs. 5.25 % 0.96
vehicle control (P < 0:01) (Fig. 3B and c). The results indicated
that the expression of PIG11 protein increased the sensitivity
of As2O3-mediated apoptosis in HEK293 cells.
3.4. Overexpression of PIG11 gene increased the generation of
ROS in HEK293 cells
Since the set of PIGs generate or respond to oxidative stress,
we examined whether PIG11 could inﬂuence the production of
ROS. Intracellular content of ROS was evaluated by the oxi-
dation of redox-sensitive ﬂuorescence probes DHE. As shown
in Fig. 4, an increase of ﬂuorescence intensity at 24 h after
transient transfection with GFP-PIG11 vector was observed.
Intracellular content of ROS was 9.66 0.52 in HEK293 cells.
In contrast, 5.21 0.08 in GFP only and 5.98 0.45 in vehicle
control (P < 0:01) (Fig. 4A).4. Discussion
The PIG11 gene was localized to human 11p11.2 and dis-
plays an unusual structure, apparently containing only oneexon. A potential p53-binding site was identiﬁed in the pro-
moter of PIG11 gene, according to our previous analysis of
known p53-binding sites (50-PuPuPuC(A/T)(A/T)GPyPyPy-30)
[19]. This DNA element consists of two decamers, there is a
minimal space between both decamers. Recently, several can-
didate liver tumor suppressor genes from this region had been
identiﬁed, using a functional model of tumor suppression. It
was reported that the transcript for PIG11 was lost or signif-
icantly decreased in some human hepatocellular carcinomas
(HepG2 and Hep3B) [20]. It suggests that PIG11 as a candi-
date liver tumor suppressor gene was existed in this chromo-
some region.
In our previous studies, we found that PIG11 was upregu-
lated markedly by As2O3 in MGC-803 cells employing the
technique of diﬀerential display reverse transcriptase PCR
(DDRT-PCR) and the apoptosis in MGC-803 by As2O3 can
partially be inhibited by means of anti-PIG11 oligonucleotide
treatment [16]. It indicated that in As2O3-induced apoptosis in
MGC-803 cells PIG11, as a downstream target of p53, may
play roles in this process. In this work, a recombinant green
ﬂuorescence protein PIG11 expressing vector was constructed
using GFP Fusion TOPO TA Expression system. When ex-
amined by ﬂuorescence microscope, GFP-PIG11 fusion pro-
tein was seen to be localized to a web of cytoplasmic ﬁlaments.
By 24 h following transfection, cells overexpressing the GFP-
PIG11 fusion protein showed substantial levels of cell apop-
tosis that was morphologically consistent with apoptosis,
showing nuclear fragmentation, but proportion of apoptotic
cells is of relatively low level.
In recent years, a number of p53 target genes have been
identiﬁed that mediate apoptosis; however, the induction of
some genes may be enough to initiate cell death, the induc-
tion of other genes by themselves will not cause the cell to
undergo apoptosis or induce apoptosis to low levels. But
recent data suggest a new class of p53 target genes that
sensitize cells to the eﬀects of chemotherapeutic agents [21],
for example, bid-deﬁcient mouse embryonic ﬁbroblasts
(MEFs) treated with increasing doses of adriamycin or 5-
ﬂuorouracil were signiﬁcantly more resistant to apopotosis
than wild-type MFFs. The p53-induced Bid could help to
sensitize the cells to toxic eﬀects of chemotherapeutic drugs
[22]. Our results demonstrated that PIG11 fusion protein
inﬂuenced apoptosis in HEK293 cells, but proportion of
apoptotic cells is relatively low level. Moreover, the increase
of PIG11 protein enhanced the sensitivity of As2O3-mediated
apoptosis in HEK293 cells. These results suggest that PIG11
is considered as a P53-chemosensitization gene and overex-
pression of PIG11 could be one of the many factors in cell
apoptosis.
On the other hand, As2O3 has become an interesting ex-
perimental therapeutics for a wide variety of hematological
as well as solid tumors [23–25]. The sensitivity of cells to
As2O3 may result from their biochemical or cellular back-
ground. Modulation of the biochemical environment of the
cells might increase the eﬃcacy of arsenic trioxide [26,27].
Some investigated that the redox system of the cell and
capacity to eliminate reactive oxygen species (ROS) are in-
volved in the eﬃcacy of As2O3[16,28–32]. ROS, such as
hydrogen peroxide (H2O2), hydroxyl radicals (OH
), super-
oxide anion radicals (O2 ), are known mediators of intra-
cellular signaling cascades. It was demonstrated that ROS
and the resulting oxidative stress play an important role in
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mediated through loss of mitochondrial membrane potential
with subsequent changes of outer mitochondria membrane
permeability, release of cytochrome c, and the activation of
caspases [29,30]. Several in vitro investigations showed that
both decreases the intracellular GSH content as well as lead to
increased intracellular H2O2 levels lead to a signiﬁcant syner-
gistic eﬀect with As2O3[31,32]. Ascorbic acid (AA) in combi-
nation with As2O3 has a potentiating eﬀect [33]. AA widely
heralded as an antioxidant. However, AA can also act as ox-
idizing agent that increases the production of ROS [34,35]. Its
capacity to undergo autooxidation results in the formation of
H2O2 that enhances the eﬀect of As2O3 [36].
To augment the apoptosis eﬀects of As2O3 in resistant tumor
cells to As2O3, potential strategies include increase of intra-
cellular ROS production [37]. We show that PIG11 expression
increased sensitivity of As2O3-mediated apoptosis in HEK293
cells and also enhanced intracellular ROS production. It is
possible that PIG11 might be valuable to increase As2O3-
sensitivity in less sensitive tumor cells may be through involved
intracellular generation of ROS. PIG11 was downregulated in
ovarian endometriosis (the disease is similar to malignant tu-
mors in some respects) [38]. The function of the protein
product of the PIG11 gene (as a negative regulation factor)
may have a role in cells apoptosis, mediated through enhanced
ROS levels.
In conclusion, PIG11 protein is a cytoplasmic protein, there
is a p53 consensus binding site in the promoter of the PIG11
gene. The overexpression of PIG11 could induce cell apoptosis
in the low levels and enhanced the apoptotic eﬀects of arsenic
trioxide. The process is involved intracellular generation of
ROS.
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